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ABSTRACT The protein component of human lipoprotein[a] consists primarily of two apolipoproteins, apo[a] and apo B-100, linked
through a cystine disulfide(s). In the amino acid sequence of apo[a], Cys4057 located within a plasminogen kringle 4-like repeat
sequence (3991-4068) is believed to form a disulfide bond with a specific cysteine residue in apo B-100. Our fluorescence-labeling
experiments and molecular modeling studies have provided evidence for possible interactions between this apo[a] kringle type and apo
B-100. The fluorescent probe, fluorescein-5-maleimide, was used in parallel experiments to label free sulfhydryl moieties in lipoprotein[a]
and low-density lipoprotein (LDL). In apo B-100 of LDL, Cys3734 was labeled with the probe, but this site was not labeled in autologous
lipoprotein[a]. The result strongly implicates Cys3734 of apo B-100 as the residue forming the disulfide linkage with Cys4057 of apo[a].
To explore possible noncovalent interactions between apo B-100 and apo[a], the crystallographic coordinates for plasminogen kringle
4 were used to generate molecular models of the apo[a] kringle-repeat sequence (3991-4068, LPaK9), the only plasminogen kringle 4
type repeat in apo[a] having an extra cysteine residue not involved in an intramolecu!ar disulfide bond. The Cys4057 residue (henceforth
designated as Cys67 in the LPaK9 sequence) is believed to form an intermolecular disulfide bond with a cysteine of apo B-100. In
computer graphics molecular models of LPaK9, Cys67 is located on the surface of the kringle near the lysine ligand binding site.
Selected segments of the LDL apo B-100 sequence that contain free sulfhydryl cysteines were subjected to energy minimization and
docking with the ligand binding site and adjacent regions of the LPaK9 model. In the docking experiments, apo B-100 segment
3732-3745 (PSCKLDFREIQIYK) displayed the best fit and the largest number of van der Waals contacts with models of LPaK9. Other
apo B-100 peptides with sulfhydryl cysteine were found to be less compatible when minimized with this kringle. These results support
and extend previously suggested mechanisms for a complex interaction between apo[a] and apo B-100 that involve more than a simple
covalent disulfide bond.
INTRODUCTION
In humans, elevated plasma levels of lipoprotein[a]
(Lp [a]) ' have been highly correlated with the incidence
of coronary and cerebral artery disease (2-5). Lp[a]
consists oftwo major and distinctly different high molec-
ular weight apoproteins (6-8). Apoprotein [a] (apo [a])
is a highly glycosylated, hydrophilic protein (7-13) with
little apparent affinity for lipid. It is disulfide-linked to
one molecule of apolipoprotein B-100 (apo B-100) (7,
10, 14), a highly hydrophobic apolipoprotein that is
partly imbedded in a lipid-rich, pseudomicellar particle.
Apo [a] has been shown to be colocalized with apo B-100
in aorto-coronary bypass vein grafts ( 15 ) and the aorta
( 16), directly implicating Lp [a] in atherosclerosis. How-
ever, neither elucidation of a positive role for Lp [a] nor
definition of the mechanism(s) by which Lp [a] leads to
atherosclerosis have been reported.
The single apo[a] polymorph whose primary struc-
ture has been inferred by cDNA sequencing (1) has a
mass of '-530 kD and consists oftwo distinct domains: a
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kringle domain and a serine protease domain. There are
38 repeated sequences in the kringle domain of this
apo[a] polymorph. Careful examination of the amino
acid sequence ofeach repeat suggests 11 different kringle
types ( 17). Kringle types 1 through 10 are similar but
not identical to plasminogen kringle 4 (PGK4). The
kringle type 2 repeat sequence (LPaK2) is serially copied
28-fold. The residues in LPaK9 and PGK4 are num-
bered 1 through 78 unlike the system used in reference
27 for PGK4 that is based on the prothrombin kringle 1
sequence of 80 residues and, therefore, contains two de-
letions. Although apo [a] kringle types 1-10 and PGK4
contain 78 residues, there exist kringle sequences in plas-
minogen and other proteins that contain >80 residues.
For a review, see Table I of reference 39. A kringle is a
highly conserved, tri-loop structure stabilized by three
disulfide bridges; its function is noncatalytic but rather
involves recognition and binding ( 18, 19). Several hemo-
stasis proteins contain the kringle motifs (20, 21 ). The
structures of kringles in apo [a] may provide insight into
the physiologic role(s) of the Lp[a] particle and help
define the mechanism(s) by which the lipoprotein ex-
presses its atherogenicity.
The three kringle structures elucidated thus far by x-
ray crystallography show a conservation of the overall
structure (22-29). These observations provide a basis
for using the three-dimensional coordinates of these
structures for evaluating other kringle-like sequences, es-
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pecially those ofapo [a] that have a high degree ofhomol-
ogy with PGK4. Therefore, we have generated models of
LPaK9 based on the coordinates of PGK4 (27) and
PGK4 liganded with e-amino caproic acid (28). Unlike
other apo [a] kringle types that contain six cysteine resi-
dues, LPaK9 contains a seventh cysteine that occurs at
position 67 and is a good candidate for the site of disul-
fide linkage to apo B-100. However, the interactions be-
tween apo[a] and apo B-100 most likely also include
noncovalent binding through one or more ofthe apo [a]
kringles (30, 31). These interactions may involve li-
gands such as L-proline and, to a lesser extent, L-lysine
(32). LPaK9 is an ideal region ofapo [a] for understand-
ing the interaction of apo [a] with apo B-100. LPaK9 is
-80% homologous to PGK4 and appears to have an
intact lysine ligand-binding site, although some of the
nonhomologous replacements are in the ligand binding
region. For example, Asp57, an essential amino acid for
the binding oflysine to PGK4, is replaced with glycine in
LPaK9. Furthermore, Trp32 and Arg35 in LPaK9,
which replace, respectively, Arg32 and Lys35 in PGK4,
influence the replication of the PGK4 ligand-binding
site by their overall mass and charge characteristics (Fig.
1). The effect of these amino acid replacements in criti-
cal positions ofthe kringle structure can be evaluated by
molecular modeling.
In this study, molecular models of LPaK9 have been
used to explain chemical data that identify regions ofapo
B-100 that may form a disulfide bond with apo [a] . Six-
teen of 25 cysteine residues in apo B- 100 occur in disul-
fide form (33), with possibly 7 other cysteine residues in
sulfhydryl form on the surface of the particle. Our ap-
proach was to label the free thiol cysteine residues of
low-density lipoprotein (LDL) and Lp[a] with a sulfhy-
dryl-specific fluorescent alkylating reagent. Trypsin-di-
gest fragments of apo B-100 from both LDL and
Lp [a-], which contained fluorescent label, were then
compared by high-performance liquid chromatography
(HPLC). LDL apo B-100 labeled fragments that were
not duplicated in similar sequence fragments of Lp[a]
apo B-100 fragments then indicated the location of the
intermolecular disulfide bond. Molecular modeling was
used to determine the structural complementarity be-
tween fragments of apo B-100 and the folded LPaK9
structure. Amino acid ligands and trypsin-releasable apo
B- 100 polypeptide fragments that contained a free thiol
cysteine residue (33, 34) were modeled along with
LPaK9. In this report we present results of the fluores-
cent labeling experiments with Lp [a] and LDL, together
with results from molecular modeling and docking ex-
periments that suggest the existence ofimportant nonco-
valent interactions between apo [a] and apo B-100.
MATERIALS AND METHODS
Materials
HPLC grade solvents were obtained from J. T. Baker (Philips-
burg, New Jersey). Spherisorb ODS II and Hypersil ODS HPLC col-
umns were purchased from Phenomenex (Rancho Palos Verdes,
California). Phenylmethylsulfonyl fluoride, sodium azide, tris-
(hydroxymethyl)-aminomethane (Tris), sodium sulfate, 6-aminohex-
anoic acid (cE-aminocaproic acid), glycerol, and ethylenediaminetetra-
acetate (EDTA) were from Sigma Chemical Company (St. Louis,
Missouri). Aprotinin (Trasylol) was from Miles Inc., FBA Pharmaceu-
ticals (West Haven, Connecticut). Lysine-Sepharose was from Phar-
macia LKB (Alameda, California). Fluorescein-5-maleimide (F5M)
were from Molecular Probes (Eugene, Oregon). Tosylphenylalanyl-
chloromethyl ketone-treated trypsin was from Worthington Biochemi-
cals (Freehold, New Jersey). Reagents and solvents for the automatic
gas-phase sequencer were products of Applied Biosystems Inc. (Foster
City, California). All other chemicals used were of the highest quality
available.
Preparation of Lp[a] and LDL
Purified Lp[a] and LDL were prepared by methods described else-
where ( 8). Lp[a] was isolated from the 1.063-1.130 density fraction by
lysine-Sepharose chromatography. This fraction, in 50 mM phosphate
buffer (pH 7.5), was applied to the affinity column that was then
washed with the same buffer until the optical density was below 0.05.
The bound Lp[a] was then eluted with 100 mM 6-aminohexanoic acid
and 500 mM sodium chloride in 50 mM phosphate buffer (pH 7.5).
LDL was prepared from the 1.020-1.063 density fraction using lysine-
Sepharose affinity chromatography to remove any contaminat-
ing Lp[a].
Fluorescein labeling of lipoprotein
particles
Free sulfhydryl groups in Lp[a] and LDL were labeled with a fluores-
cent probe using a slight modification of the method described previ-
ously (35). Briefly, to 20.0 mg ofLp [a] (in -20 ml) or LDL (concen-
tration was usually >2.0 mg/ml) was added 2.5 ml 1.0 M Tris-acetate
and 10 mM EDTA, pH 7.6, 0.35 g sodium sulfate, 32.2 mg 6-amino-
hexanoic acid, 2.5 ml glycerol, and 7.2 mg FSM. The total volume of
the reaction mixture was adjusted to 25 ml with nanopure grade water.
The samples were gently agitated in darkness at 30°C for 16 h.
Unreacted F5M was removed using a Sephadex G25 (fine pore) col-
umn (2.5 cm ID x 40 cm h) that had been equilibrated with several
volumes ofthe Tris-acetate-EDTA buffer. The labeled lipoprotein peak
eluted from the column in the void volume and was collected as a single
fraction. Each preparation was made 20.0 mM dithiothreitol and 10.0
mM 6-aminohexanoic acid and reduction was allowed to proceed at
ambient temperature for 3 h. Potassium bromide was then added to
each sample to obtain a solution density of 1.120 for separating the
labeled LDL and labeled Lp[a- ] particles from nonlipoproteins. Cen-
trifugation was performed using an ultracentrifuge (model L8-80;
Beckman Instruments, Fullerton, California) and a 50.2 Ti rotor at
40,000 rpm for 22 h.
The labeled LDL and labeled Lp[a-] that floated to the top of the
centrifuge tubes were collected and dialyzed against 6 liters of nano-
pure water with at least three changes. Pellets of higher density protein
such as apo[aJ were also collected, resuspended in nanopure water,
and dialyzed as before. Each sample was then shell frozen and lyophi-
lized. Lyophilized powders were delipidated using an ethanol:diethyl-
ether ( 1:3) solvent mixture as described previously (8). No fluores-
cence was detectable in the apo[a] samples after delipidation.
Tryptic digestion
Delipidated apo B-100 from LDL and from Lp[a- ] were hydrolyzed
using L-1-p-tosylamino-2-phenylethyl chloromethyl ketone-treated
trypsin as described by Coleman et al. (35).
Polypeptide isolation
Tryptic polypeptides were separated by HPLC as described earlier
(34). Briefly, aliquots of the digest mixture were first applied to a VY-
Guevara et al. Model of LPaK9 and Apo B-100 Linkage 687e a] Model of LPaK9 and Apo B-100 Linkage 687
151
10
1n0
FIGURE I Sequence comparison ofhuman plasminogen kringle 4 and
apo[a] kringle type 9. The 16 residue replacements in the apo[a] krin-
gle type 9 are shown outside the circled PGK4 residue.
DAC (Hesperia, California) C4 6.25 mm ID x 25 cm 1 reverse-phase
column. Peptides were eluted with a linear 1% per minute gradient ofa
trifluoroacetic acid buffer system (A, 0.1% trifluoroacetic acid [TFA]
in water; B, 0.08% TFA in 95% acetonitrile and 5% water). Each fluo-
rescent polypeptide peak was collected and then applied to a Phenom-
enex 5 ,uM Hypersil ODS 4.6 mm ID X 25 cm 1 column and eluted
with a sodium phosphate buffer, pH 6.0 (solvent A), and
acetonitrile:water, 9: 1, (solvent B) system linear gradient (34). Further
purification of the fluorescent peptide was accomplished by rechro-
matographing the isolated peak on the Phenomenex column using the
same eluting system, except that solvent A was at pH 4.0. All chroma-
tography was conducted at 50°C. Ultraviolet adsorption was moni-
tored at 220 nm and fluorescence at 515 nm using Applied Biosystems
Inc. detectors.
Sequence analysis of fluorescent
peptides
Sequence analysis of the fluorescent peptides was performed as de-
scribed by Coleman et al. (35) using an Applied Biosystems Inc. auto-
mated gas-phase sequencer.
Molecular modeling systems and
methods
Modeling was performed on molecular graphics workstations from Sili-
con Graphics Inc. (Mountain View, CA) and Evans and Sutherland,
Inc. (Salt Lake City, UT) using the crystallographic modeling programs
CHAIN (36), Polygen Corporation's (Waltham, MA) QUANTA 3.0,
and the Adopted Basis Newton-Raphson energy minimization proce-
dure in CHARMm (version 21 ). There are 16 amino acid substitutions
in LPaK9 that distinguish this apo[a] kringle from PGK4 (Fig. 1 ).
Five of these substitutions are also present in nine other apo [a] kringle
types that are similar to PGK4. The five substitutions that are con-
served in PGK4-like kringles of apo[a] are Val17, Arg2O, Thr21,
Arg35, and Thr76. There are 11 additional residue replacements in
LPaK9 that may lead to slight structural differences from PGK4. In
PGK4, Lys2O-Lys21 and Lys76-Lys77 ofPGK4 are replaced with argi-
nine-threonine and threonine-glutamine in LPaK9. In PGK4, Thr29
and Arg32 are changed to isoleucine and tryptophan in LPaK9; these
two residues occur on the surface of the kringle. In addition, Lys35,
AlaSS, Asp56, and Gly58 of the ligand binding region of PGK4 are
altered to arginine, serine, glycine, and glutamine in LPaK9.
The effect of the above changes on the kringle structure was studied
using several different approaches to produce models of LPaK9. One
approach involved adding each amino acid residue at the appropriate
alpha-carbon coordinates to the x-ray crystallographic structure of
PGK4; the amino acid side groups were added without positional bias,
i.e., chi torsion angles were the default all-trans form ofthe Alchemy II
program (Tripos Associates, St. Louis, MO). The alpha-carbon atoms
were held fixed as the model was then subjected to energy minimiza-
tion. All the atoms were then allowed to move, and the molecule was
refined further. This model is henceforth referred to as the unbiased
LPaK9 model. A second approach was to use the complete PGK4
crystallographic structure and make the 16 amino acid substitutions
required to convert the molecule to LPaK9 (Fig. 1). The structure of
the molecule was then refined as previously described. This model is
referred to as the biased LPaK9 model. Typically, amino acids such as
tryptophan, tyrosine, and phenylalanine were regularized to maintain
strict aromatic ring planarity within CHAIN (36) before the final en-
ergy minimization was applied. Although other models of LPaK9
based on PGK4 were studied, only these two models ofLPaK9 (biased
and unbiased) are described in the present report.
Amino acids phenylalanine, proline, leucine, and arginine were min-
imized positioned in the ligand-binding site of the biased LPaK9
model. Trypsin-releasable LDL apo B-100 sequences (34) containing
cysteine residues that were selected for ligand docking experiments
with the biased LPaK9 model are listed in Table 1. Apo B-100 frag-
ments were constructed using the programs Sequence Builder and Pro-
tein Design (Polygen Corp.). Several different approaches were used in
modeling fragments of apo B-100 with the biased model of LPaK9. In
one approach, fragments of eight amino acids, with the cysteine in
position 3, were constructed for determining the sequence that formed
the most contacts with residues adjacent to LPaK9 Cys67, residues
between Cys67 and the ligand-binding site, and residues within the
binding site (i.e., Arg35, Asp54, Gly56, Trp6O, Arg69, Trp70, and
Tyr72). In a second approach, the previous method was repeated but
with a distance constraint of 2.0 A imposed for a disulfide bond be-
tween the LPaK9 Cys67 and the apo B-100 fragment. This complex
was then minimized with the kringle held fixed. After several cycles of
minimization, the distance constraint was removed and the complex
was subjected to further minimization. Finally, the kringle itself was
released and one cycle of minimization was performed.
A third approach was intuitive and based on the results obtained
through the fluorescent labeling experiments. Apo B-100 fragment
3732-3746 (Table 1) of 15 amino acids was generated and contoured
on the surface ofthe kringle with Phe3738 placed in the ligand-binding
TABLE 1 Polypeptide fragments from apo B-100 containing
unbound cysteine residues used in molecular docking
experiments with models of LPaK9
NHK1073ITEVALMGHLSCDT L1083SCDTKEERKIKGVI
T1383TYDHKNTFTLSCDG L1393SCDGSLRHKFLDSN
S1466SFYAKGTYGLSCQR L1476SCQRDPNTGRLNGE
D1623GISTSATTNLKCSL L1633KCSLLVLENELNAE
F3722HVPFTDLQVPSCKL P3732SCKLDFREIQIYKK
K3878ADYVETVLDSTCSS S3888TCSSTVQFLEYELN
P4178GKPGIYTREELCTM E4188LCTMFIREVGTVLS
NH, direction of amino terminus. Underlined residues were placed in
the ligand-binding site of LPaK9 with the residue nearest the free cys-
teine in the Trp60/Trp7O region.
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site. Contouring or shaping of the fragment was accomplished by tor-
sioning bonds and minimizing the fragment before placing it on the
surface of the kringle. The cysteine of the fragment was placed proxi-
mal to Cys67 ofLPaK9 without constraints, and the resulting complex
was subjected to minimization. An additional protocol was used for
apo B-100 fragments containing Cys3734 and Cys3890 to determine
their complementarity with another region of the biased LPaK9 krin-
gle. In this case, dipeptides were added to the eight amino acid frag-
ments generated in the above constructions starting at the ligand-bind-
ing site (i.e., Ile3741Gln to Glu3740 and Val3842Glu to Thr3"4). Several
minimization cycles were then performed after each addition.
RESULTS
Indirect chemical evidence of the
LPaK9 disulfide linkage to apo B-100
Previously, Coleman et al. (35) identified two free cys-
teine residues in LDL apo B-100 at positions 3734 and
4190 using the fluorescent probe, 5-iodoacetamidofluo-
resceine. In the present study, Lp[a] and LDL were
treated with F5M, a thiol specific reagent, to determine
the difference in number and location ofthe free sulfhy-
dryl groups in apo B-l00 for each lipoprotein. The
probe, F5M, was selected for these experiments because
it is water soluble, thiol specific, and easily detectable.
Although there are slight differences between the chro-
matograms of tryptic peptides from LDL apo B-100 and
Lp [a-] apo B- 100 detected at 220 nm, the elution pro-
files shown in Fig. 2, A and B share many common peaks
and both are highly reproducible. In LDL, an apo B-100
fragment containing Cys3734 was labeled with F5M as
had been shown previously (35). Apo B-100 fragments
containing Cys4190, shown as fluorescent peaks 30-33,
were weakly labeled in both LDL and Lp [a- ]. Fluores-
cent peaks 1-29 (Fig. 2, Cand D) were previously shown
not to contain a cysteine residue (35). Although the
peak patterns as determined by absorbance at 220 nm
are similar in the two peptide chromatograms (Fig. 2, A
and B), there are some apparent differences in the fluo-
rescence chromatograms (Fig. 2, Cand D). The Lp [a- ]
fluorescence chromatogram (Fig. 2 D) shows different
labeling of noncysteine containing peptides, i.e., dif-
ferent labeling of other nucleophilic amino acids
such as lysine. Fluorescent peaks 35 and 36 shown in
Fig. 2 C contain the apo B-100 tryptic peptide
cleaved at Lys3735 and include the sequence
L37,0NDLNSVLVMPTFHVPFTDLQVPSCK3735. The
apo B-100 Cys3734 is the labeled residue in this tryptic
peptide. These results are identical to those reported pre-
viously for apo B-100 in LDL from a different donor
(35). Similar A220n,m absorbance patterns were obtained
for tryptic peptides from apo B-100 in Lp[a-] eluted
from the column (Fig. 2 B). In contrast, fluorescent
peaks 35 and 36 were prominent in the LDL apo B-100
fluorescence chromatogram (Fig. 2 C) but were barely
discernible in the Lp [a-] apo B- 100 fluorescence chro-
matogram (Fig. 2 D). These results indicate that
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FIGURE 2 HPLC chromatograms of the tryptic peptides of F5M la-
beled apo B-100 from LDL (A and C) and from Lp[a-] (B and D).
Primary separation of tryptic peptides was performed on a Vydac C4
column (6.25 x 250 mm) using a TFA buffer system. Previous amino
acid analysis of peaks 1 through 29 showed these to be fluorescent
peptide or tryptic peptides that did not contain a Cys residue (35).
Fluorescent peaks 35 and 36 are tryptic peptides resulting from apo
B-100 cleavage at Lys3735 and both peptides contain Cys3734.
Cys4190 is present in fragments that eluted as peaks 30 through 33;
Cys4190 was labeled weakly in apo B- 100 from both LDL and Lp[aJ].
Cys3734 of apo B-l00 in Lp[a] is involved in a disulfide
linkage.
Molecular modeling of LPaK9 and apo
B-100 interactions
We considered it plausible that Cys3734 of apo B-100
forms a disulfide linkage with Cys67 of LPaK9 to form
an Lp[a] particle. Therefore, molecular models of
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TABLE 2 CHARMm potential energy (kcal/mol) calculations for
PGK4 and minimized molecular models of LPaK9
LPaK9
PGK4 Biased Unbiased
Total E -2,516 -2,538 -2,486
Bond E 23 22 25
Angle E 184 114 150
Dihedral E 260 215 279
Improper E 41 38 44
van der Waals E -194 -222 -195
Electrostatic E -2,831 -2,697 -2,788
LPaK9 were generated by making the appropriate
amino acid side chain substitutions onto the PGK4 poly-
peptide backbone (unbiased model) as well as on the
complete PGK4 structure (biased model). Before per-
forming the docking experiments with apo B-100 frag-
ments, each LPaK9 model was evaluated to determine
the influence(s) the 16 amino acid alterations had on the
structure of the complete kringle and its ligand binding
site.
Modeling of LPaK9
Each LPaK9 model was subjected to several cycles of
energy minimization until values comparable with those
ofPGK4 were obtained. Energy values shown in Table 2
for both LPaK9 models strongly support the probability
that this segment ofapo [ a ] exists in a kringle conforma-
tion. Comparisons of the C-alpha trace of each LPaK9
model with that ofPGK4 were used to identify regions of
the kringle where amino acid alterations cause a shift in
the main chain. A schematic comparison of the C-alpha
trace structure ofPGK4 with those of the two models of
LPaK9 is shown in Fig. 3. Although some shifts are seen
between the biased LPaK9 model and PGK4, the unbi-
ased LPaK9 shows changes throughout the main chain
ofthe kringle. Shifts in the main chain appear to occur in
both LPaK9 models at the putative ligand-binding re-
gion of the kringle. The largest shifts occur in the main
chain of the unbiased LPaK9 model (purple) in the re-
gions adjacent to positions 8, 17, 57, and 68. These main
chain changes are at or near sites of amino acid alter-
ations. The shifts are more pronounced in the main
chain ofthe unbiased LPaK9 model and probably reflect
the lesser degree of constraints imposed in building that
model. However, residues that form the hydrophobic
clusters and are known to stabilize the structure in
PGK4 (27) are highly conserved in LPaK9 and must
impart stability in a similar manner. The rms deviations
of atoms of the main chain and aromatic and proline
side groups were determined from a comparison of the
LPaK9 models with PGK4 (Table 3). The values indi-
cate that positional deviations of the side groups are
again greater between the unbiased LPaK9 model and
PGK4 than for those of the biased LPaK9 model and
PGK4. These results show a change in the nature of
FIGURE 3 Schematic comparison of the C-alpha trace structure of
PGK4 with LPaK9 molecular models. The C-alpha trace of the unbi-
ased LPaK9 model (purple) is superimposed on the trace structure of
PGK4 (green). The C-alpha trace of unbiased LPaK9 model was gen-
erated by making residue side group additions to the PGK4 mainchain.
Prominent shifts of the polypeptide main chain are indicated for this
LPaK9 model in the putative ligand-binding region at positions 8, 17,
57, and 68 and to a lesser degree at other sites in the kringle. The
C-alpha trace of the biased LPaK9 model is shown in yellow. Small
positional deviations are observed throughout the mainchain of this
model as well.
overall hydrophobic core of the unbiased kringle struc-
ture that may, along with dihedral angles, indicate a less
stable conformation. The Ramachandran angles of the
unbiased and biased models ofLPaK9 (Fig. 4, A and B)
also suggest this possibility. The phi/psi angle distribu-
tion for the biased LPaK9 indicates that this model con-
forms well to allowed regions of the plot, whereas the
unbiased LPaK9 has several residues in unfavorable re-
gions. Several main chain changes in the biased LPaK9
TABLE 3 Comparison of rms deviations of LPaK9 models from
PGK4 hydrophobic core residues
Main chain rms (A) Side group rms (A)
Residue Amino
position acid Unbiased Biased Unbiased Biased
2 Tyr 1.1 0.9 3.4 0.5
9 Tyr 1.2 0.5 2.3 0.8
25 Trp 1.5 0.4 1.6 0.5
33 His 1.4 0.3 4.9 0.7
37 Pro 1.0 1.1 1.1 1.2
40 Tyr 1.1 0.5 2.7 0.9
45 Leu 0.7 0.6 1.7 0.9
53 Pro 1.0 0.4 1.2 0.9
59 Pro 0.7 0.5 1.5 0.6
60 Trp 0.6 0.8 2.7 0.7
62 Phe -Tyr 0 0 0 0
70 Trp 1.5 0.3 7.1 0.9
72 Tyr 0.6 0.3 1.8 1.1
75 Leu 1.9 1.0 5.5 1.2
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Two possible ligand-binding sites in models
of LPaK9
The models predict two different possible ligand-binding
sites for LPaK9. In the unbiased LPaK9 model, residues
in positions 57, 60,62,69,70, and 72, which are integral
to the ligand-binding region ofthe kringle, maybe forced
into another energetically favorable conformation. The
significant residue changes occurring in the ligand-bind-
ing region of LPaK9 are Trp32, Arg35, Ser55, Gly56,
and Tyr62. Since Asp56 is not conserved in LPaK9, the
two models of this kringle present potential ligand-bind-
ing sites that are different from the same region in
PGK4. The ligand binding site of the unbiased LPaK9
model shows orientations of Trp6O and Trp7O that are
different from the corresponding region in PGK4 struc-
ture (Fig. 5, orange). In the model ofbiased LPaK9 (Fig.
5, blue), the amino acid side chains ofTrp6O and Trp7O
are positioned as in PGK4. In the LPaK9 models, Trp32
and Arg35, which replace Arg32 and Lys35 of PGK4,
respectively, appear to influence the gross fidelity of the
PGK4 ligand-binding site by their overall mass, charge
characteristics, and orientation. Both models suggest
that LPaK9 binds a bulkier and nonpolar ligand such as
an aromatic residue. The ligand-binding sites of both
LPaK9 models are more spacious than that of PGK4
and may even accommodate two residues. Although the
two LPaK9 models were minimized with different
amino acids placed in the ligand-binding site space-fill
experiments and in docking experiments with fragments
ofapo B- 100, only results ofexperiments with the biased
LPaK9 model, which may be a more valid representa-
tion of the actual structure, are discussed.
Modeling of LPaK9 with free amino acid
ligands
Expectedly, phenylalanine, proline, and leucine were
found to "fit" well as free ligands in the trough formed
FIGURE 4 Ramachandran plots of the unbiased (a) and biased (b)
models of LPaK9. Glycine residues are boxed and residues with unac-
ceptable angles are identified.
model agree with the torsional angles in the Ramachan-
dran plot. In PGK4, only Met47 falls into nonallowed
regions ofthe Ramachandran plot, whereas in the biased
LPaK9 model, Glu47, Ser55, and Cysl are located in
nonallowed regions. In cont-rast, the Ramachandran plot
of the unbiased LPaK9 shows that the dihedral angles
are outside of energetically allowed regions (Ser8, Tyr9,
ArglO, Glu47, Lys57, Cys67, Trp7O, Glu71, Asn74).
The structural differences ofthe unbiased model are also
reflected by the positional differences in the main chain
of the kringle.
FIGURE 5 Stick models ofthe binding regions ofthe unbiased (orange)
and biased (blue) models of LPaK9. A striking difference is evident in
the putative ligand-binding regions of the models that reflect the rms
values for Trp 60, Trp 70, and Tyr 72, shown in Table 3.
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by Trp6O and Trp7O of the ligand-binding site. Free li-
gands of lysine and arginine were observed to be rotated
as much as 90° when placed with the carboxyl moieties
proximal to the cationic region of the binding site. In
some cases the guanidino group of arginine and the E-
amino group oflysine were observed to fold back to form
a salt bridge with the delta-carboxyl group of Asp54. In
these instances, a major portion of the ligand-binding
site is left unoccupied in the nonpolar region (i.e., Gly56
and Trp6O and Trp7O near Tyr72).
Modeling of possible interactions between
LPaK9 and apo B-100
In LPaK9, Cys67, which probably forms the disulfide
with apo B- 100, is on the surface of the kringle between
the putative ligand-binding site and a region rich in aro-
matic and hydrophobic residues. The latter region is
composed of Met28, Ile29, Pro3O, Trp32, and Pro66. A
multi-faceted interaction between LPaK9 and apo
B- 100 that involves the ligand-binding site, the kringle
surface adjacent to the binding site and Cys67, and the
disulfide bond appeared to be possible. The polypeptide
fragments ofapo B-l00 shown in Table 1 were subjected
to energy minimization with the LPaK9 model as a
docking template to determine which fragment(s) had
the best fit with the ligand binding site and surface of
LPaK9.
Assessment of "best fit" was based on total number of
contacts between the fragment and the LPaK9 model,
lowest potential energy values after minimization, and
dihedral main chain angles for the fragment. Apo B-100
fragment P3732SCKLDFR was repeatedly shown to be
the most complementary peptide with the kringle. Typi-
cally, lower potential energy values were achieved when
the kringle with the apo B- 100 fragment was subjected to
minimization. Although these initial modeling experi-
ments with the shorter fragments were not rigorously
minimized, this fragment was shown to have a high num-
ber of contacts with Phe3738 having 14 good contacts
with Trp6O and Trp7O. The high contact total was then
confirmed through a second method in docking and
minimization experiments in which distance constraints
between the cysteine residues were imposed and the
kringle was held fixed. Results shown in Table 4 indicate
that apo B-100 fragment P3732SCKLDFR had the lowest
potential energy and 90 atom contacts, with phenylala-
nine having 21 with the critical ligand-binding site resi-
dues of Trp6O and Trp7O. Apo B-100 fragment
L1393SCDGSLR displayed 96 atom contacts and the sec-
ond best potential energy value. The leucine and argi-
nine residues of this fragment had 41 contacts with resi-
dues ofthe ligand-binding site but none with Trp6O; argi-
nine showed 33 contacts with kringle residues Gln3O,
Arg35, Asp54, Ser55, and Gly56 on the periphery of the
ligand-binding site. Although this apo B-100 fragment
shows many contacts with the kringle model ligand-
binding site, practically all contacts are in one region of
the site, leaving a large portion of the site vacant. Apo
B-100 fragment L,083SCDTKEE also has 95 atom con-
tacts with a good potential energy value; however, the
cysteine residue ofthe fragment is located at an unfavor-
able distance from the kringle Cys67. Three fragment
residues are located within the kringle ligand-binding
site. Although many contacts were observed for Tyr1474
for the apo B-100 fragment containing Cys1478, few
contacts were evident for the other residues of this frag-
ment. In addition, Met 1080, located on the amino termi-
nal side of CyslO85, also displayed a high number of
uniform contacts with the kringle ligand-binding site resi-
dues, but less complementarity was evident with the
other residues in this apo B- 100 fragment.
Two approaches were used in modeling the kringle
with larger apo B-100 fragments. The best results were
obtained in docking experiments and energy minimiza-
tion of apo B-100 fragment P3732SCKLDFREIQIYKK
with the biased LPaK9 model. Results in Table 5 show a
uniform interaction between residues of apo B-100
fragment P3732SCKLDFREIQIYKK and the biased
LPaK9 model ligand-binding site and surface. About
188 molecular contacts were identified in docking
experiments in which the apo B-100 fragment
P3732SCKLDFREIQIYKK was contoured on biased
LPaK9 model (Figs. 6 and 7). Only 30 contacts were
evident between the unbiased LPaK9 and this fragment
ofapo B-100. Significantly, 139 nonhydrogen bond con-
tacts between the LPaK9 model and this apo B-100 frag-
ment were between 3.5 and 4.0 A. Forty-nine contacts
were <3.5 A, but there were no van der Waals contacts <
2.9 A. The first residue of the fragment, Pro3732, was
shown to have 26 total contacts with Pro3O, His31,
Asp65, Pro66, Cys67, and Arg69 of LPaK9. Apo B-100
Pro3732 has 16 nonhydrogen bond contacts between 3.5
and 4.0 A and 10 contacts < 3.5 A with the biased model
of LPaK9. The ligand residue, Phe3738, displayed 29
total contacts, between 3.5 and 4.0 A, with only one con-
tact of 2.94 A at Phe CE2 and Asp54 ODl. This suggests
that Phe3738 fits well within the ligand-binding site of
this LPaK9 model when it is located at position 7 in this
apo B-100 fragment. Contact points shown in Table 5
suggest that LPaK9 Pro3O, His3 1, Pro66, Cys67, and
Arg69 may interact with residues in positions 1-4 ofthe
apo B-100 fragment with cysteine in position 3. LPaK9
Gln34, Arg35, Asp54, Gly56, Tyr62, Trp6O, and Trp7O
form the ligand-binding site and interact with hydropho-
bic residues such as phenylalanine and leucine in frag-
ment position 7 and with residues in fragment positions
8 and 9. To identify LPaK9 residues that might interact
with fragment residues in positions 9-15, dipeptides
were added to the fragment residue nearest the cationic
periphery of the ligand-binding pocket, i.e., His33,
Gln34, and Arg35. Obviously, one possibility was that
the fragment polypeptide would be minimized orthogo-
nal or away from the kringle surface. The second possibil-
ity was that the fragment polypeptide would build on the
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TABLE 4 Apo B-100 cysteine-containing fragments minimized with the biased LPaK9 model
T E V A L M G H
R35 Y62 W32
D54 H33
G56 Q34
W60 R69
W70
Y72
L S C D
R69 P66 P30
C67 H31
P66
Contacts 21 01 17 00 11 04 19 00
C D T K E E R K I K G V
C67 R69 D54 R35 Q34 CyslO85
R69 W70 W60 D54 R35 TC 95
W70 D54 TE -2697
Y62
R69
45 Contacts03 04 00 10 07 24 02
Y D H K N T F T L S C D G
Q34 D54 R69 R69 P66 P66 P66 H31
W60 C67 C67 W32
Y62 R69
W70
Contacts 04 14 02 02 10 11 01 22
S C D G S L R H K F L D S
P66 R69 W32 Q34 R35 Q34 Cys1395
C67 H33 R35 D54 R35 TC 96
R69 R69 Y62 Y62 D54 TE -2878
R69 W70 S55
G56
09 00 14 09 08
S S
Cys1478
TC81
TE -2826
15 08 33 Contacts
F Y A K G T Y G
D54 R35 R69
S55 D54
G56 G56
K57
W60
W70
Y72
L S C Q R D
P66 P66 R69 V68 R69
C67 W70 W70
L S C Q R
R69 P66 P30 P66
Contacts 16 38 05 00 13 02 06 01
P N T G R L N G E
Q34 Cys1478
R35 TC 74
Y62 TE -2858
R69
00 01 07 13 12 16 00 25 Contacts
D G I
Cys1635
TC 38
TE -2767
LS T S A T T N L K C S
Q34 R35 W70 R69 R69 P66
R35 D54 W70 C67
D54 W60
Y62 Y62
W70
Contacts 10 13 02 08 02 03 00 00
L K C S L L V L E N E L N A E
P66 P66 P66 R69 W70 Y62 Q34 Cysl635
C67 C67 W70 R69 R35 TC 41
R69 W70 TE -2787
12 Contacts
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K I
CyslO85
TC 69
TE -2794
L S
D65 C67
C67
T
I
T T
Cys1395
TC 66
TE -2749
L
P66
C67
N
00 03 03 07 05 03 08
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TABLE 4 (continued)
F H V P F T D L Q
Cys3734 D54
TC 38 W60
TE -2799 Y62
W70
V P S
R69 C67 P66
C67
R69
Contacts 00 16 03 01 12 00 06 00
D F
W70 D54
G56
W60
W70
R E I
R35 Cys3734
D54 TC 90
TE -2917
Q I Y K K
08 12 09 00 14 04 21 22 Contacts
D Y V E T V
Q34
R35
L D S T
W70 Y62 R69 P66
R69 C67
R69
Contacts 04 03 20 03 07 07 04 21
C S S T
R69 R69 Y62 R35
R69 D54
W60
Y62
W70
V
W60
W70
Q F L E Y E L N
Cys3890
TC 49
TE -2786
00 06 03 08 08 17 07 00 Contacts
P G K P G
Cys4190
TC 64
TE -2909
Y T R
R69 R35
D54
W60
Y62
R69
W70
E E L
W70 R69 H31
P66
C67
R69
Contacts 04
L C
P66
T M
R69 W32
R69
F I
W32 R35
Y62
R69
W70
26 07 15 07 03 02
R E V G T V L S
R35 Cys419O
D54 TC 46
TE -2853
03 00 03 05 08 05 05 17 Contacts
Apo B-100 fragments of eight amino acids were constructed to determine total contacts (TC) with residues adjacent to LPaK Cys67, those residues
between Cys67 and the ligand-binding site, and residues with the binding site (e.g., P66 is LPaK9 Pro66). A distance constraint of2.0 A was imposed
between LPaK Cys67 and the cysteine ofthe apo B-100 fragment (e.g., CyslO85). Fragments were constructed two residues per minimization cycle.
Final total energy values are shown as TE.
surface of the kringle and suggest which kringle residues
interact with the docking polypeptide. Thereby, a com-
plement polypeptide sequence would evolve. LPaK9
Met28, Trp32, Gln34, Thr36, and Glu38 would appear
to interact with nonpolar residues in fragment positions
11-15. However, a polar residue such as aspartate in
fragment position 13 may turn the fragment away from
the kringle surface. This result was observed using the
apo B-100 fragment containing Cys3890 (Table 5).
Other regions ofapo B-100 that contain unbound cys-
teine residues were also studied, and less atom contact
points with less favorable potential energy values were
observed after minimization with this LPaK9 model.
For example, the graphic in Fig. 8 shows the
biased LPaK9 model with apo B-100 fragment
L1476SCQRDPNT1484 minimized to a location outside
the binding site and apart from the kringle. This apo
B-100 fragment contains a Pro( 1482) that is located
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P S
P30 P30
H31
P66
R69
C
P66
C67
R69
C K
P30
P66
L
K L
C67
V68
R69
W70
K A
Cys3890
TC 69
TE -2806
S T
P66
C67
C
P30
H31
P66
S S
P30 I29
P30
W32
E
P66
C67
C T
C67 P66
C67
M
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TABLE 5 Apo B-100 Cys3734 and Cys3890 containing fragments minimized with the biased LPaK9 model
I. The apo B-100 15 residuefragment was constructed and contoured on kringle with Phe3738 in ligand-binding site.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
P S C K L D F R E I Q I Y K K
P30 C67 P66 C67 V68 V68 R35 R69 H33 Q34 W32 S27 M28 M28 M28
H31 C67 V68 W70 R69 D54 Q34 R69 H33 M28 T36
D65 R69 W70 W60 R35 Q34 H31 E38
P66 Y62 Y62 W32
C67 W70 R69 H33
R69 T36
05 06 05 26
(01) (03)
29 01 39 07 09
(09) (02) (03)
16
(01)
II. The apo B-100 15 residuefragment was constructed by adding dipeptides in the carboxyl-terminal direction to Arg3739 in the kringle ligand-
binding site. Each addition step wasfollowed by a minimization cycle.
1 2
P S
3
C
4
K
5
L
6
D
7
F
8
R
9
E
10 11 12
Q I
13
y
14
K
15
K
P30 P30 P66
H31 H31 C67
P66 R69
R69
R69 G56 R35 Q34
W70 W60 D54 R35
W70 R69
D54
W32 W32 M28
Q34 W32
T36
E38
09 12 05
(03) (03) (02)
Cys3734
TC 103
TE -3351
00 00 11
(01)
15 10 11
(03) (05)
III. The apo B-100 15 residuefragment was constructed by adding dipeptides in the amino-terminal direction to Val3885 in the kringle ligand-
binding site. Each addition step wasfollowed by a minimization cycle.
15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
K A D Y V E T V L D S T C S S
Q34 Q34 Q34 Q34 D54 G56 Y62 R69 C67 H31 P30 129
N39 R35 R35 G56 K57 R69 R69 P66 H31 P30
Y40 Y40 D54 W60 W70 C67 D65 W32
Y62 W70 R69 P66
Y72
00 00 00 06 04 10 18 08 22 25 06 10 12 16 13
(01) (02) (04) (05) (01) (07) (02) (O1) (02) (07) (02)
Cys3890
TC 150
TE -3127
Contacts between the apo B-i 00 fragment residues (single letter) and the LPaK9 residues (e.g., Q34) are shown in each column. Hydrogen bond
contacts are shown in parenthesis. Total number of contacts (TC) between the fragment and LPaK9 include van der Waals and hydrogen bond
contacts. The final total energy values (TE) shown in the table reflect values after minimization was performed on the LPaK9 and the complete apo
B-100 fragment.
four residues from Cys1477. This proline was placed in B-100 fragment and the LPaK9 models is suggested by
the hydrophobic ligand-binding site of the kringle, and the few contact points with the ligand-binding site resi-
the disulfide bond between LPaK9 Cys67 and apo B- 100 dues Trp6O and Trp7O. This example also shows the im-
Cys 1477 was formed before energy minimization. An portance ofthe dihedral angles for residues placed in the
unusually high potential energy value was computed be- ligand-binding site. This program is designed to adjust
fore minimization. The minimization process moved angles and bond lengths to reach the most favorable en-
the fragment away from the kringle but was constrained ergy levels, and, in this instance, the lowest energy levels
by the disulfide bond. Incompatibility between this apo for both the proline of the apo B- 100 fragment and the
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Cys3734
TC 188
TE -3458
16 01 01
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00 08
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FIGURE 6 Stereogram of the biased LPaK9 model showing residues that interact with apo B-100 fragment P3732SCKLDFREIQIYKK. The
fragment was contoured on the kringle with Phe stacked between Trp6O and Trp7O before minimization.
kringle model are achieved only with the fragment away
from the kringle.
DISCUSSION
The amino acid sequence of apo [a] inferred by the
cDNA sequence ( 1 ) suggests the presence of 11 different
types of kringles, with 10 kringle types being similar but
not identical to PGK4 (17, 40). We have assumed that
(a) there exists a high degree of homology among all
kringles, (b) there is the conservation of specific residues
in determined positions that define the kringle motif,
and (c) there is especially high sequence homology be-
tween apo [a] kringle sequences and PGK4. Based on
these assumptions, it is reasonable to predict that the
apo [a] PGK4-like sequences also exist in a kringle con-
formation. Although there is no direct evidence at pres-
ent demonstrating that these repeated sequences exist in
the typical tri-loop kringle conformation, it is known
that prothrombin kringle 1, plasminogen kringles 1 and
4, and tissue plasminogen activator kringle 2, which
share - 50% sequence homology, occur in the same
kringle conformation. Therefore, operating on this as-
sumption we have developed molecular models of the
FIGURE 7 Space-filled model of apo B-100 fragment 3732-3745
docked to biased LPaK9.
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FIGURE 8 Stereogram of the biased LPaK9 with apo B-100 fragment 1476-1489. This apo B-100 fragment contains Pro 1481 that is located four
residues from Cys1477 and was docked in the hydrophobic ligand-binding site ofthe kringle. The Pro 1481 can be seen outside the binding site with
no apparent contact points after energy minimization.
LPaK9 sequence as a kringle to gain a clearer under-
standing ofthis sequence both as a kringle type and as an
important site on apo [a] for the kringle interaction with
apo B-100 in the forming Lp [a]. Our second assump-
tion is that because the overall kringle side chain struc-
ture appears to be the same for conserved residues in
PGK4 and prothrombin kringle 1 (27), these structures
also may be conserved in apo [a]. Although refinement
of molecular structures by nonhydrated, static energy
minimization can yield secondary and tertiary structures
that are energetically favorable but are different from the
true structure, at present it is still the best method for
evaluating structures that have not been elucidated by
x-ray crystallographic or multidimensional nuclear mag-
netic resonance methods. Furthermore, molecular mod-
eling provides a reasonable prediction ofother structures
that may actually exist. Our models are based on coordi-
nates ofthe crystallographic structure for PGK4 and are
presented here as predicted structures of LPaK9.
We have used these predicted LPaK9 structures in
computer graphics ligand site space-filling and docking
experiments with fragments of apo B-100 to visualize
possible molecular interactions that may exist between
apo B-100 and apo [a]. Several schemes can be consid-
ered to explain how apo [a] and apo B- 100 interact in the
intact Lp[a] particle. The most basic is limited simply to
the formation of a single connecting covalent disulfide
bond and proposes that the remainder ofthe apo [a] mol-
ecule floats freely in the aqueous environment about the
lipoprotein particle. A second mechanism involves, in
addition to the connecting disulfide, ligand-binding of
the two molecules through the kringle domain ofapo [a]
and specific binding sites on apo B-100. For example, a
lysine-containing region on apo B-100 might bind
through ionic and van der Waals forces directly with a
ligand-binding site on one or several apo [a] kringles. A
third mechanism involves electrostatic interactions be-
tween the highly sialylated, negatively charged apo [a]
and the positively charged apo B- 100 of the particle.
Although it has not yet been demonstrated directly by
amino acid sequence analysis, there is strong evidence
that apo [a] is covalently linked to apo B-100 ( 7-11, 14,
37). We have performed experiments that identify indi-
rectly a cysteine residue on apo B- 100 that forms a disul-
fide bond with apo [a]. Our results show that in labeling
Lp[a] with F5M, only the Lp[a-] particle was labeled.
This suggests that a cysteine residue in LPaK9 thought
not to be paired within the apo [a] molecule may form a
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disulfide bond with apo B-100 in the intact Lp [a]. Al-
though our results indicate that Cys3734 is labeled in
LDL but is not labeled in Lp[a] and suggest that this
cysteine residue is involved in disulfide linkage between
the two apoproteins, direct evidence from sequence anal-
ysis has not yet been obtained. Whether Cys3734 ofapo
B-100 forms a disulfide bond exclusively with apo[a]
has not been determined. It is possible that this cysteine
residue of apo B-100 may form a disulfide bond with
other apolipoproteins such as apoE or apoD or form a
thioester linkage with fatty acids (38).
Several noteworthy aspects of LPaK9 that are evident
in its primary structure are then graphically revealed by
our molecular models. LPaK9 has a ligand-binding site
similar to, yet different from, that of PGK4 and hence
may not be involved in binding to a positively charged
ligand such as lysine, arginine, or histidine located either
on apo B- 100 or another protein. Although the majority
of the apo[a] kringle types are similar to PGK4, only
LPaK1O appears to retain the critical amino acid se-
quence required for binding a lysine ligand. We have
modeled several free amino acids in the binding site of
LPaK9 to identify those that best fill and complement
the site. Results of space-fill and minimization experi-
ments with single amino acids as free ligands were incon-
clusive. Although energetically favorable models were
attained with some free amino acids, the orientation of
amino acids such as proline, lysine, and arginine within
the site was visibly not convincing. For example, proline
minimizes well with LPaK9 models but only partially
fills the apparent ligand-binding site space. Lysine and
arginine are minimized into a "curled" conformation to
form a salt bridge with Asp54 of the kringle and hence
only a part ofthe site is occupied. Space-fill and minimi-
zation experiments with amino acids leucine and phenyl-
alanine, as free ligands, in the ligand-binding site of the
biased LPaK9 model showed energetically favorable and
visibly acceptable models; low potential energy values
for the complex with many atom contacts between the
ligand and amino acids that form the ligand-binding site.
However, it is unlikely that this type of interaction is of
physiologic importance. The ligand amino acid is more
likely part of a polypeptide and involves other adjacent
amino acids.
In Lp[a], we considered a mechanism that involves
both covalent disulfide bonding and noncovalent inter-
actions between a specific site on apo B-100 and a spe-
cific amino acid such as leucine, methionine, tyrosine, or
phenylalanine. Although 14 apo B- 100 fragments (Table
1) were examined, only six regions were expected to be
compatible with LPaK9: Cys 1395 with Phe 1391 or
LeuI399, Cysl478 with Tyrl474, Cys1635 with
Val1639, Cys3734 with Phe3738, Cys3890 with
Leu3886 or Val3894, and Cys4190 with Ile4194. Two
apo B-100 fragments containing Cys3734 and Cys3890
are part ofan epitope recognized by monoclonal antibod-
ies, Bsol 15 and Bsol20, reported by Zawadzki et al. (39).
Their results show a slight increase in immunoreactivity
for these antibodies with the apo [a] -free Lp [a-] as
compared with the intact Lp[a]. The location of this
epitope on apo B-100 is at 3506-4082 and contains 576
amino acids. Only 29 residues, -5%, contained within
this apo B-100 fragment were not released into an
aqueous medium after trypsin digestion of LDL (29).
Furthermore, 35% of the remaining residues were
found in both hydrophilic and hydrophobic media after
trypsin digestion ofLDL (29), which suggests a flexibil-
ity in conformation as well as in its microenvironment.
Although it appears that all the disulfide bonds of apo
B-100 occur on the surface in the trypsin-releaseable
peptides ofthe LDL particle (34), there are no disulfides
located in this region of the apo B-100 molecule. It is
possible that in Lp [a], the interaction between apo [a]
and apo B-100 may be restricted to LPaK9 and to 15 or
less residues on apo B-100 within this epitope.
Systematic energy minimizations of free ligands and
ligands as part of polypeptides filling the ligand-binding
space in the biased LPaK9 model strongly suggest that
fragment P3732SCKLDFREIQIYKK is the site of inter-
action between apo [a] and apo B-100 in Lp[a]. This
interaction is based on complementarity that involves
(a) the covalent disulfide bond formed between apo
B-100 Cys3734 and LPaK9 Cys67, (b) the interaction of
apo B-100 Phe3738 with Trp6O and Trp7O within the
ligand binding site of LPaK9, and (c) the electrostatic
and van der Waals interactions between the apo B-100
fragment and the surface of LPaK9 adjacent to the li-
gand-binding site and Cys67. Molecular energy refine-
ment (dihedral energy, bond length energy, van der
Waal energy) was enhanced by the presence of the apo
B-100 fragment, and many contact points between these
LPaK9 models and this apo B-100 fragment were identi-
fied. Although minimization was not hindered by the
combination ofthe LPaK9 model with a noncompatible
apo B-100 fragment, the fragment and kringle typically
moved apart and basically minimized separately. Molec-
ular energy refinement ofnoncomplementary structures
was therefore accomplished with the two molecules
apart. An example of this result is demonstrated with
fragment L1476SCQRDPNTGRLNGE (Fig. 8).
Proline, an amino acid that is thought to be more im-
portant than lysine in the binding of apo [a] and Lp [a]
to biotinylated-LDL (32), was also modeled with
LPaK9, alone and within apo B-100 fragment 1476-
1490. In our models, proline appears to occupy only a
fraction of the apparent space in the binding site of
LPaK9. As a part of apo B-100 fragment 1476-1490,
proline appeared to be minimally compatible with
LPaK9. It is likely that proline, when added in excess,
interferes with the interactions between apo[a] and bio-
tinylated-LDL by competing with a proline on apo
B- 100 that binds to a different apo [a] kringle type such
as the highly repeated type 2 (LPaK2). The critical an-
ionic residue, Asp56 in PGK4, is replaced by glycine in
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LPaK2, a change that influences the dipolarity and size
of the kringle binding site. There are 78 proline residues
in the trypsin-releasable peptides of apo B-100 from
LDL (34), 56% ofwhich are located near the NH2-termi-
nal end. Little is known about the function of proline
residues in apo B-100. It is possible that some prolines
are located in exposed structural loci such as beta-turns
that would render these residues sterically accessible for
interacting with ligand-binding sites of apo [a] kringles.
Alternatively, it is possible that excess proline disrupts
the hydrophobic core of the kringle (27) formed by the
numerous proline, histidine, and aromatic residues that
may be conserved in some apo [a] kringles and, thereby,
alter the geometry of the kringle ligand-binding site. In
bovine prothrombin kringle 1 and PGK4, there are histi-
dine and proline residues that form discrete clusters
(27). Exogenous proline or hydroxyproline may disrupt
these histidine/proline clusters. Ifsuch clusters also exist
in apo [a] kringles, altering their structure by proline
would be expected to interfere with their binding capac-
ity. One such cluster includes residues Pro3O, His3 1, and
Pro66, which are conserved in apo[a] kringle types
1 through 10. In docking experiments with the
biased LPaK9 model and apo B-100 fragment
P3732SCKLDFREIQIYKK, Pro3732 appears to have
contact points with Pro3O, His3 1, Asp65, Pro66, Cys67,
and Arg69. There are several other key residue alter-
ations in this region of the kringle such as I1e29 and
Trp32 that along with Met28, Pro66, and Val68 create a
more hydrophobic environment. This region may inter-
act with the apolar regions adjacent to the Cys3734 apo
B-100 fragment and/or the lipid phase ofthe LDL parti-
cle. Alternatively, this site may be a ligand-binding re-
gion in some kringles.
CONCLUSIONS
Based on energy minimization calculations, it is clear
that an LPaK9 sequence is capable ofassuming a molecu-
lar conformation similar to that of PGK4 determined
crystallographically. Two molecular models of LPaK9
were obtained through minimization methods with ener-
getically favorable values that are comparable with those
of PGK4. The more plausible and acceptable model of
LPaK9, with few unfavorable dihedral angles, was the
biased one generated by simply altering the 16 amino
acid substitutions on the complete PGK4 molecule. Ma-
jor sites on the kringle such as the ligand binding region
are influenced by the character ofthe residues located at
or near that region. Therefore, it is not surprising that,
since PGK4 and LPaK9 have different amino acid resi-
dues in this region, the two kringles have binding sites of
apparently different ligand specificity and/or affinity.
Molecular docking experiments with models of
LPaK9 and apo B-100 fragments that contain a free cys-
teine lead us to propose that the interaction between
apo[a] and apo B-100 in Lp[a] involves three aspects:
(a) LPaK9 forms a covalent disulfide bond at Cys3734;
(b) there are molecular contacts, electrostatic interac-
tions, hydrogen bonds, and van der Waals interactions
between specific amino acids on the face of LPaK9 and
that ofLDL apo B-l00; and (c) a kringle-ligand complex
forms between apo B-100 Phe3738 and the ligand-bind-
ing site of LPaK9.
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